Industry Challenges Impede Cancer Research

August 28, 2007
Industry Challenges Impede Cancer Research

"We discovered that industry has tried to use DQA to challenge every aspect of the NTP scientific review and release process," said Clayton Northouse, Information Policy Analyst at OMB Watch. "Special interest associations have challenged meetings, press releases, notices to study specific chemicals and other documents that are clearly beyond the parameters of DQA. Instead of seeking to improve the quality of data, the intent of these challenges seems to be to keep scientific information out of the hands of health professionals and government decision-makers."